Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 511-523

  Ogata, Norio ^b   Zanetti, Alessandro R ^b   Minshu, Yu ^b   Miller, Roger H ^b   Purcell, Robert H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIGEN;

ANIMAL MODEL; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS MUTATION;

EID: 0031019778     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.511     Document Type: Article

References (16)

1. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-41.
2. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units. Efficacy and subtype cross-protection. N Engl J Med 1982;307:1481-6.
3. Xu ZY, Liu CB, Francis DP, et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-8.
4. Wheeley SM, Boxall EH, Tarlow MJ, et al. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: final report on a West Midlands pilot study. J Med Virol 1990;30:113-6.
5. Beasley RP, Hwang LY, Lee GCY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
6. Wong VCW, Ip HMH, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: double blind randomized placebo-controlled study. Lancet 1984;1:921-6.
7. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985;253:1740-5.
8. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-6.
9. Gerety RJ. Recombinant hepatitis B vaccines. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R Liss, 1988:1017-24.
10. Purcell RH, Gerin JL. Hepatitis B vaccines: a status report. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978:491-505.
11. Koziol DE, Alter HJ, Kirchner JP, Holland PV. The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol 1976;117:2260-2.
12. Swenson PD, Escobar MR, Carithers RL Jr, Sobieski TJ III. Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection. J Clin Microbiol 1983;18:305-9.
13. Linnemann C, Askey PA. Susceptibility to hepatitis B despite high titre anti-HBs antibody. Lancet 1984;1:346-7.
14. Wands JR, Fujita YK, Isselbacher KJ, et al. Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci USA 1986;83:6608-12.
15. Coursaget P, Yvonnet B, Bourdil C, et al. HBsAg positive reactivity in man not due to hepatitis B virus. Lancet 1987;2:1354-8.
16. Zanetti AR, Tanzi E, Manzillo G, et al. Hepatitis B variant in Europe. Lancet 1988;2:1132-3.